STRATIFY JCV Antibody (with Index) with Reflex to Inhibition Assay
Use
Detection of antibodies to John Cunningham Virus (JCV) in human serum or plasma is used in conjunction with other clinical data (e.g., multiple sclerosis or Crohn’s disease patients receiving natalizumab) to aid risk stratification for progressive multifocal leukoencephalopathy (PML) development.
Special Instructions
Not provided.
Limitations
Affected by specimen quality issues such as gross hemolysis, lipemia, or icterus. Indeterminate index values require reflex inhibition testing for confirmation; negative results do not rule out new exposure over time.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
JCV Antibody Index
Analyte
Result Turnaround Time
4-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.0 mL preferred; 0.5 mL minimum
Minimum Volume
Not provided
Container
Serum gel (SST) tube preferred; lavender (EDTA) or red top acceptable; aliquoted into plastic vial
Collection Instructions
Centrifuge and aliquot serum into plastic vial promptly; separate within 45 minutes
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 90 days |
Other tests from different labs that may be relevant